Max E. Hallin
Impact in
- Oncology top 10%
- Chemokine receptors and signaling
- Cancer-related Molecular Pathways
-
- Cancer Genomics and Diagnostics
- Cancer, Hypoxia, and Metabolism
Papers in
- Co-authors
- David A. Rewolinski (1 shared paper)Karin Amundson (2 shared papers)Maren L. Grazzini (2 shared papers)Dana D. Hu‐Lowe (2 shared papers)Patrick M. O’Connor (1 shared paper)Xinglin Wu (1 shared paper)David R. Shalinsky (1 shared paper)Jeffrey H. Chen (1 shared paper)
- Journals
- Clinical Cancer Research (2 papers)Nature Communications (2 papers)Blood Advances (1 paper)Blood (1 paper)Cancer Research (1 paper)
- Partner nations
- United States
In The Last Decade
Max E. Hallin
8 papers receiving 738 citations
Peers
Comparison fields: 5 of 79
- Oncology 274
- Cancer Research 110
- Pulmonary and Respiratory Medicine 231
- Molecular Biology 313
- Hematology 45
Countries citing papers authored by Max E. Hallin
This map shows the geographic impact of Max E. Hallin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Max E. Hallin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Max E. Hallin more than expected).
Fields of papers citing papers by Max E. Hallin
This network shows the impact of papers produced by Max E. Hallin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Max E. Hallin. The network helps show where Max E. Hallin may publish in the future.
Co-authors
The 25 scholars most cited alongside Max E. Hallin, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2008 | 557 | |
| 2 | 2017 | 52 | |
| 3 | 2009 | 48 | |
| 4 | 2017 | 44 | |
| 5 | 2023 | 38 | |
| 6 | 2014 | 8 | |
| 7 | PF-00337210, a potent, selective and orally bioavailable small molecule inhibitor of VEGFR-2 | 2007 | 7 |
| 8 | 2025 | 4 |
About Max E. Hallin
Max E. Hallin is a scholar working on Oncology, Genetics, Hematology, Pulmonary and Respiratory Medicine and Cancer Research, having authored 8 papers that have together received 758 indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (2 papers), Chronic Lymphocytic Leukemia Research (2 papers), Cancer Immunotherapy and Biomarkers (2 papers), Renal cell carcinoma treatment (2 papers), Chemokine receptors and signaling (2 papers), Angiogenesis and VEGF in Cancer (2 papers), Single-cell and spatial transcriptomics (1 paper) and Microtubule and mitosis dynamics (1 paper). The work is most often cited by research in Oncology (274 citations), Cancer Research (110 citations), Pulmonary and Respiratory Medicine (231 citations), Molecular Biology (313 citations) and Hematology (45 citations). Max E. Hallin has collaborated with scholars based in United States. Frequent co-authors include David A. Rewolinski, Karin Amundson, Maren L. Grazzini, Dana D. Hu‐Lowe, Patrick M. O’Connor, Xinglin Wu, David R. Shalinsky, Jeffrey H. Chen, Robert S. Kania and Helen Y. Zou. Their work appears in journals such as Clinical Cancer Research, Nature Communications, Blood Advances, Blood and Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.